Saturday 08 Aug, 2020 06:15 AM
Site map | Locate Us | Login
   Sobha records 93% drop in Q1 PAT to Rs 7 cr    Mahanagar Gas slips after weak Q1 performance     Magma Fincorp Ltd leads losers in 'A' group    AMJ Land Holdings Ltd leads losers in 'B' group    Alembic Pharma raises 750 cr from QIP issue    Volumes jump at JSW Energy Ltd counter    M&M Q1 PAT slumps 97% to Rs 68 cr    Healthcare stocks edge lower    Information Technology stocks slip    Consumer Durables shares fall    KEI Inds Q1 PAT slides 21% to Rs 36 cr    Bajaj Holdings & Investment Ltd soars 1.39%, Gains for third straight session    GAIL (India) Ltd gains for third consecutive session    Tata Motors Ltd soars 1.16%    Bosch Ltd spurts around 3.50% 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Sun Pharma records Q1 net loss of Rs 1656 cr
31-Jul-20   15:41 Hrs IST

Net sales declined 9.6% on a year-on-year (YoY) basis to Rs 7,467.19 crore in the first quarter of the financial year 2020-21. Research and development expenses rose 2.1% YoY to Rs 415.19 crore in Q1 June 2020.

Profit before tax and exceptional items fell 12% to Rs 1,449.43 crore in Q1 FY21 from Rs 1,647.44 crore in Q1 FY20.

The company recorded an exceptional expenditure of Rs 3,633.33 crore during the quarter ended 30 June 2020 on account of settlement of civil antitrust matters by Taro Pharmaceuticals U.S.A., Inc., Sun Pharma's subsidiary, with the United States' Department of Justice and certain other provisions relating to the same.

Pre-tax loss in Q1 FY21 stood at Rs 2,183.90 crore as against a pre-tax profit of Rs 1,647.44 recorded in the same period last year.

Tax expenses for the June quarter increased by 68.4% to Rs 245.91 crore compared with Rs 146.06 crore incurred in Q1 June 2019.

Meanwhile, the drug major's board approved the scheme of amalgamation and merger between the company and Sun Pharma Global FZE (wholly owned subsidiary of the company). It envisages merger of Sun Pharma Global FZE into the company. The scheme shall be effective post receipt of required approvals and accordingly, the above results do not reflect the impact on account of the scheme, Sun Pharma said.

The combined entity will have a bigger portfolio of products and direct access to markets, which will strengthen its capabilities to serve more efficiently its customers. This will also enable the SPIL address the competitive regulatory environment, risks and policies, better management of supply chain, better product profiling, greater differentiation, ability to strategize the Business for long term growth, the company said in a statement.

Shares of Sun Pharma jumped 4.27% to Rs 531.75 on Friday. It traded in the range of 507.75 and 540.75 during the day.

Sun Pharmaceutical Industries is a specialty generic manufacturing pharma company.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.G Anand , anand@ssplwealth.com
Hit Count : 14626346
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd